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Abstract
Background: Bovine spongiform encephalopathy (BSE), a member of the transmissible spongiform encephalopathies (TSE),
primarily affects cattle. Transmission is via concentrate feed rations contaminated with infected meat and bone meal (MBM). In
addition to cattle, other food animal species are susceptible to BSE and also pose a potential threat to human health as
consumption of infected meat products is the cause of variant Creutzfeldt-Jakob disease in humans, which is invariably fatal. In
the UK, farmed and free ranging deer were almost certainly exposed to BSE infected MBM in proprietary feeds prior to
legislation banning its inclusion. Therefore, although BSE has never been diagnosed in any deer species, a possible risk to human
health remains via ingestion of cervine products. Chronic wasting disease (CWD), also a TSE, naturally infects several cervid
species in North America and is spreading rapidly in both captive and free-ranging populations.
Results: Here we show that European red deer (Cervus elaphus elaphus) are susceptible to intra-cerebral (i/c) challenge with
BSE positive cattle brain pool material resulting in clinical neurological disease and weight loss by 794–1290 days and the clinical
signs are indistinguishable to those reported in deer with CWD. Spongiform changes typical of TSE infections were present in
brain and accumulation of the disease-associated abnormal prion protein (PrPd) was present in the central and peripheral
nervous systems, but not in lymphoid or other tissues. Western immunoblot analysis of brain material showed a similar
glycosylation pattern to that of BSE derived from infected cattle and experimentally infected sheep with respect to protease-
resistant PrP isoforms. However, the di-, mono- and unglycosylated bands migrated significantly (p < 0.001) further in the
samples from the clinically affected deer when compared to BSE infected brains of cattle and sheep.
Conclusion: This study shows that deer are susceptible to BSE by intra-cerebral inoculation and display clinical signs and
vacuolar pathology that are similar to those of CWD. These findings highlight the importance of preventing the spread to Europe
of CWD from North America as this may necessitate even more extensive testing of animal tissues destined for human
consumption within the EU. Although the absence of PrPd in lymphoid and other non-neurological tissues potentially limits the
risk of transmission to humans, the replication of TSE agents in peripheral tissues following intra-cerebral challenge is often
limited. Thus the assessment of risk posed by cervine BSE as a human pathogen or for environmental contamination should await
the outcome of ongoing oral challenge experiments.
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Background
Bovine spongiform encephalopathy (BSE), which affects
cattle and several other food animal species [1,2], belongs
to the transmissible spongiform encephalopathy (TSE)
group of fatal neurodegenerative diseases affecting
humans and animals [3,4] and can be transmitted within
and between species by ingestion or parenteral inocula-
tion [5]. TSEs which include, amongst others, scrapie in
sheep and goats, sporadic Creutzfeldt-Jakob disease (CJD)
in humans and chronic wasting disease (CWD) of deer [6]
are all characterised by long incubation periods leading to
clinical neurological manifestations. The pathological
changes can usually be linked with the conversion of the
normal host-encoded membrane associated prion protein
(PrPC) to abnormal disease-associated isoforms (PrPd)
and their accumulation in the nervous system and,
depending on the host species and the TSE agent involved,
the lymphoreticular system [7]. Detection of PrPd in tis-
sues by various laboratory methods is the current
approach for a definitive diagnosis of any TSE [8].
Ten years after the first report of BSE in cattle [9] variant
Creutzfeldt-Jakob disease (vCJD) was diagnosed in
humans in the UK [10] and is invariably fatal [11]. Inges-
tion of BSE contaminated bovine products was subse-
quently linked to the development of vCJD [12] resulting
in greatly intensified surveillance and research in both
humans and food animals [13].
During the 1980s UK farmed deer were fed relatively large
amounts of proprietary concentrate feed containing rumi-
nant derived meat and bone meal (MBM) due to the mar-
ket demand for well grown breeding stock. Additionally,
some free ranging estate deer, park deer and cervids of
many different species kept in UK zoological collections
were also fed similar proprietary concentrate feed (pers
com. Dr. T.J. Fletcher). It is highly unlikely that these con-
centrates were free from BSE contaminated MBM suggest-
ing that UK deer have been exposed to infectious material.
Surveys of several thousand deer brains have so far
revealed no evidence of any sub-clinical TSE infection in
deer in Europe. This is despite the presence in North
America of CWD, a highly infectious TSE which specifi-
cally affects deer including the elk (Cervus elaphus nelsoni),
a sub-species of European red deer, and is currently the
only TSE maintained in free ranging populations [14].
However, the European surveys have either not concen-
trated on farmed populations, been regionally restricted,
had limited numbers or have not specifically targeted clin-
ical neurological suspects [15-20].
Results
In the present study 6 European red deer (Cervus elaphus
elaphus), the most commonly farmed cervid species in the
UK, were challenged intracerebrally (i/c) with BSE posi-
tive bovine brain material and a further 2 deer received
sterile saline by the same route. All deer on the study were
methionine homozygous at codon 132 of the cervid prion
protein [21] equivalent to codon 129 in humans [22]. All
six BSE-inoculated animals developed a variable range of
neurological clinical signs including ataxia, anorexia, cir-
cling and apparent blindness along with failure of sea-
sonal change of coat, weight loss and 'panic attacks'
between 794–1300 days post-challenge (Table 1). The
panic attacks comprised various episodes of mania of dif-
fering severity and duration, which in the first and last ani-
mals to develop clinical signs resulted in self trauma
requiring euthanasia on welfare grounds. Five of the
affected deer were euthanased and one (deer No. 5) died
of inhalation pneumonia. With the exception of very little
intra-thoracic or abdominal adipose tissue, which was
apparent in all animals, gross lesions were present only in
the animal that died of inhalation pneumonia. Severe
consolidation of the right apical lung lobe was present
with red/green discolouration, the tissue was very friable
and a low-viscosity purulent material oozed from the cut
surface. Also, blood was present in the caecum of this ani-
mal.
Spongiform change characterized by vacuolation of both
neuronal perikarya and grey matter neuropil was promi-
nent in the brains of all six clinically affected deer (Figure
1). Optically empty, round or oval vacuoles were present
in neuropil while neuronal perikaryonal vacuoles were
sometimes loculated and sometimes contained membra-
nous debris. The appearance and distribution of the vacu-
oles are thus indistinguishable from those of other
classical TSEs, including CWD. Lesions predominantly
affected the brain stem, thalamus and striate body, as well
as the molecular layer of the cerebellum and cerebrocorti-
cal layers V and VI.
Immunohistochemical labelling of PrPd
Accumulation of PrPd  in the BSE infected deer was
restricted to the central and peripheral nervous systems,
including all levels of the spinal cord, the autonomic gan-
glia, peripheral and cranial nerves, the enteric nervous sys-
tem and the sensory retina. Essentially the same
neuroanatomic pattern and types of PrPd accumulation
were found with each of the two antibodies (F99 and Bar
224) that were used. PrPd deposits were more inconsistent
and less intense in the first deer to show clinical signs
compared with the other five, possibly due to its shorter
incubation period (794 days, Table 1). PrPd was found to
accumulate in all anatomical areas of the brain though
levels were relatively lower in the cerebral cortex. Typi-
cally, only grey matter was involved, with the most prom-
inent accumulations being of the fine particulate type,
with some more coarse and linear deposits in severely
affected areas (Figure 2). Granular deposits of PrPd withinBMC Veterinary Research 2008, 4:17 http://www.biomedcentral.com/1746-6148/4/17
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the cytoplasm of neurons were prominent, especially
throughout the brainstem and thalamic nuclei, though
they were less conspicuous in the striate body and cerebral
cortex. In the cerebellum, accumulation of intra-neuronal
PrPd was conspicuous in the deep nuclei and, distinctly, in
the Golgi neurons of the granular layer, but not in the
Purkinje cells (Figure 3). Intracellular deposits of PrPd
were also noticeable in astrocytes and microglial cells in
areas of heavy neuropil involvement. In the cerebral grey
matter, the PrPd around glial cells produced a diffuse stel-
late pattern of accumulation. Very little PrPd accumulation
was present around blood vessels in cerebral white matter
or as intra-astrocytic granules in the cerebellum. PrPd was
not detected in lymphoreticular tissues, skeletal muscle,
kidneys or any of the other organs examined.
Western immunoblotting
Western immunoblot analysis of individual samples of
cerebellum from the 6 clinically affected deer using anti-
body L42 after treatment with proteinase K showed a gly-
cosylation pattern of protease-resistant PrP (PrPres) in
Patterns of PrP d accumulation in the brain of clinically  affected BSE challenged deer Figure 2
Patterns of PrPd accumulation in the brain of clini-
cally affected BSE challenged deer. PrPd immunohisto-
chemical labelling of the vestibular nuclei using Bar 224 
antibody shows that the neuropil has severe particulate and 
linear deposits of PrPd accumulation (brown pigment denotes 
PrPd). There is also marked intraneuronal labelling present 
(arrow). Bar = 100 μm.
Table 1: Clinical parameters of BSE infection in deer.
Clinical parameters Deer identification
1 2 3 4 5678
Incubation period (challenge-PME date) (days) 794 930 996 996 1060 1290 1017 1290
Clinical signs duration (days) 21 100 105 77 85 22 N/A N/A
Weight loss (peak weight to PME [kg]) 12.9 20.0 19.8 19.1 24.3 11.5 9.6 0.5
Weight loss (as % of peak weight) 13.2 27.3 20.4 21.8 39.2 11.9 10.3 0.6
A t a x i a + + + + + + + +---
A n o r e x i a - + + + + + ---
Circling - + ++ ++ ----
F a i l u r e  o f  s e a s o n a l  c h a n g e  o f  c o a t - + + + ----
A p p a r e n t  b l i n d n e s s - - + + ----
Panic attacks +++ ++ + - - ++ - -
Inhalation pneumonia - - - - +++ - - -
Deer 1–6 challenged i/c with BSE agent in chronological order of developing clinical signs. Deer 7 and 8 challenged i/c with sterile saline – negative 
control animals.PME = post-mortem examination N/A = not applicable-negative, + mild, ++ moderate, +++ severe
Spongiform change in the obex of the brain from a clinically  affected BSE challenged deer Figure 1
Spongiform change in the obex of the brain from a 
clinically affected BSE challenged deer. Note the opti-
cally empty vacuoles in both neuronal perikarya (black 
arrows), occasionally containing membranous debris, and 
also the neuropil (red arrows). Haematoxylin and eosin. Bar 
= 50 μm.BMC Veterinary Research 2008, 4:17 http://www.biomedcentral.com/1746-6148/4/17
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which the di-glycosyl fraction predominated (Figure 4
and Table 2) with some minor variations in labelling
intensity between animals. The deer di-, mono- and ung-
lycosylated bands migrated significantly (p < 0.001) fur-
ther than the corresponding bands in both the cattle and
experimental ovine BSE samples, which in turn migrated
significantly more than ovine scrapie. None of the BSE-
infected samples, irrespective of the species of origin
(bovid, ovid or cervid), reacted with antibody P4 in an
identical Western immunoblot but the sample of scrapie
infected ovine brain did (data not shown). The lack of
labelling by antibody P4 is a recognised method of differ-
entiation between ovine BSE and scrapie derived PrPres
[23]. Additionally, all cervid samples did label with anti-
body P4 in the absence of proteinase K treatment indicat-
ing that PrPC is detected by this method in all species
examined (data not shown). This absence of detection of
cervid PrPres after proteinase K treatment by the P4 anti-
body is consistent with immunoblot characteristics of
other experimental ruminant BSE infections and some
experimental sheep scrapie sources such as CH1641 [24].
Discussion
This is the first report of the successful experimental trans-
mission of BSE to any species of deer and the first report
of any TSE in European deer. European red deer were cho-
sen because in the UK they are the cervid species most
commonly given supplementary proprietary feed under
both farmed or free-ranging estate management and
therefore are the species most likely to have been exposed
to BSE contaminated MBM prior to its exclusion from ani-
mal feed. Additionally, they are very closely related to the
North American elk which is susceptible to CWD [14].
The resultant clinical signs in the BSE challenged red deer
were similar to those reported in both naturally acquired
and experimental CWD in cervids in North America,
including death due to secondary inhalation pneumonia
[14]. As such, we believe it would not be possible to dif-
ferentiate BSE, if it occurred naturally, from CWD in deer
by routine clinical examination in the field.
The vacuolation pattern found in the brains of the BSE
challenged red deer is similar to that reported in cattle
with BSE except that the mesencephalon appeared to be
more affected in the latter [13]. Sheep orally infected with
BSE also developed a similar vacuolation pattern which
favours the brainstem [25] as do mule deer (Odocoileus
hemionus) and elk with clinical CWD [26] such that the
patterns of vacuolation in the brain are unlikely to pro-
vide a simple method to distinguish between individual
BSE or CWD infections in deer.
PrPd labelling by IHC in tissues from the clinically affected
i/c BSE challenged red deer showed it to be restricted to
the central and peripheral nervous systems. This suggests
an incubation-period related centrifugal spread of infec-
tivity from the brain and associated PrPd accumulation
through the nervous system. Overall, the immunohisto-
chemical features of BSE in red deer after i/c transmission
are similar to those reported for cattle, sheep or goats nat-
urally or experimentally infected with BSE, in which there
is prominent intra-cellular PrPd accumulation as well as
widespread particulate labelling in areas of grey matter
neuropil, including that surrounding the soma of neurons
and their processes along with linear and multifocal stel-
late reticular forms associated with glial cells [13]. Follow-
Table 2: Mean relative percentage intensities of labelled PrPres di-, mono- and aglycosyl bands from Western blots
Immunolabelled band Natural Scrapie Ovine BSE Bovine BSE Deer 1 Deer 2 Deer 3 Deer 4 Deer 5 Deer 6
diglycosyl 44 54 62 57 50 51 52 46 61
monoglycosyl 36 31 26 32 35 34 33 35 32
a g l y c o s y l 2 0 1 5 1 2 1 11 51 61 51 9 7
Intraneural PrP d accumulation in Golgi neurons of clinically  affected BSE challenged deer Figure 3
Intraneural PrP d accumulation in Golgi neurons of 
clinically affected BSE challenged deer. PrPd immuno-
histochemical labelling of the cerebellar cortex using Bar 224 
antibody shows accumulation in granular and molecular lay-
ers. There is prominent intraneuronal PrPd accumulation in 
Golgi neurons (arrow). Linear forms of accumulation are also 
present, one of which is associated with a Golgi neuron cell 
body (brown pigment denotes PrPd). Bar = 100 μm.BMC Veterinary Research 2008, 4:17 http://www.biomedcentral.com/1746-6148/4/17
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ing high dose oral challenge of cattle several studies have
also shown an inconsistent presence of BSE infectivity or
PrPd labelling in some peripheral nerves, Peyer's patches
and tonsils [27,28]. However, the infectivity in both neu-
ral and non-neural tissues from BSE affected deer follow-
ing oral challenge is yet to be determined. Sheep that have
been challenged orally with bovine derived BSE differ
from both cattle and i/c challenged red deer in that they
show extensive labelling of PrPd in lymphoid tissues in
addition to the peripheral and central nervous systems
[25] similar to deer with CWD [14].
In contrast to our findings in BSE infected red deer where
prominent intra-neuronal labelling of PrPd was found,
intra-neuronal deposits are reportedly rare in CWD
affected animals and when present are mild and scattered
within and between neurones of different nuclei; mainly
in the brainstem [29] and the cerebellar deep nuclei [30].
However, detailed descriptions of the neuropathology of
different CWD sources are few and it is not clear whether
CWD consists of a single or many TSE strains. Whether
BSE in deer can be readily distinguished by IHC epitope
mapping [31] or PrPd profile [32] will require additional
study.
Differentiation of BSE from CWD in deer would appear
possible by IHC as PrPd is restricted to the nervous system
in BSE yet present in the lymphoid tissue in CWD. How-
ever, the red deer in this study were experimentally chal-
lenged by the i/c route and we cannot be certain of the
distribution of PrPd in deer exposed to natural, presuma-
bly oral, challenge with BSE.
Western immunoblot analysis of the brains from the 6
affected red deer showed that the PrPres pattern of i/c cer-
vid BSE has similarities to cattle BSE including a relatively
fast migrating aglycosyl band and predominance of the di-
glycosyl band (Figure 4). The greater intensity of labelling
of deer 5 may be due to it dying, and therefore reaching a
terminal end point, rather than a clinical end point where
animals were euthanased at an agreed severity of clinical
signs, as occurred in the previous four affected deer. Also,
deer 5 was the only female in the BSE i/c challenge group,
however, we are uncertain if this had any effect on PrPres
glycoprofile or levels of accumulation. The significantly (p
< 0.001) greater migration of all three protease resistant
bands (di-, mono- and unglycosylated) in the red deer
samples compared to the cattle and sheep BSE suggests
some host adaptation of BSE PrPres propagated within the
red deer nervous system. The altered biochemical proper-
ties suggests the possibility of alternative truncation of the
PrP molecule within deer compared with the bovine or
ovine host.
Conclusion
This study shows that European red deer are susceptible to
i/c challenge with the BSE agent resulting in a disease that
is clinically indistinguishable by routine clinical examina-
tion from that reported for CWD [14]. Thus strong meas-
ures to prevent the spread of CWD to Europe are essential
as even small numbers of CWD cases could result in the
need for extensive testing of deer tissues destined for
human consumption.
The susceptibility of UK red deer to natural, presumably
oral, exposure is still uncertain. The absence of PrPd in
lymphoid tissues in the present work might appear to
limit the risk to humans of infection from venison and
other non-neuronal edible deer tissues and also limits the
maintenance of natural infection in the environment.
However, the susceptibility of peripheral tissues to infec-
tion cannot be ascertained from i/c challenge and must
await the outcome of parallel oral challenge experiments.
Methods
Animal procedures
Eight European red deer calves were housed at 1–2 days
old, initially hand reared with artificial milk and then
given ad-libitum access to water, hay and proprietary con-
centrated feed when weaned. All experimental protocols
Glycosylation patterns of PrPres Figure 4
Glycosylation patterns of PrPres. Western immunoblot 
of brain samples after treatment with Proteinase-K and using 
antibody L42 (R-biopharm, diluted 1/2000) to label protein-
ase resistant PrP. Note significantly (p < 0.001) greater 
migration of di-, mono- and unglycosylated bands in all 6 clin-
ically affected deer (lanes 5, 6, 8–11) compared to sheep 
scrapie, experimental ovine BSE and cattle BSE (lanes 2–4 
respectively). Also, lack of labelling of protease resistant PrP 
in negative control deer (lanes 7 and 12). Lane 1 – molecular 
weight markers (kDa), lane 2 – sheep scrapie, lane 3 – exper-
imental ovine BSE, lane 4 – BSE (inoculum), lane 5 – clinically 
affected deer 1, lane 6 – clinically affected deer 2, lane 7 – 
negative control (deer 7 in table 1), lane 8 – clinically affected 
deer 3, lane 9 – clinically affected deer 4, lane 10 – clinically 
affected deer 5, lane 11 – clinically affected deer 6, lane 12 – 
negative control (deer 8 in table 1), lane 13 – molecular 
weight markers (kDa).BMC Veterinary Research 2008, 4:17 http://www.biomedcentral.com/1746-6148/4/17
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were approved by the Moredun Research Institute Animal
Experiments Ethical Committee and authorised under the
UK Animals (Scientific Procedures) Act 1986. One half ml
of a 10% solution of BSE brain material (BBP12/92,
which consisted of a pool of 5 BSE positive bovine brains
with comparative titres of 106.0 cattle [i/c] units LD 50/g
and 103.3 mouse [i/c/intra peritoneal] units LD 50/g, VLA-
Weybridge, UK) diluted in sterile normal (0.9%) saline
and containing 1.25 mg/ml ampicillin was inoculated
into the right cerebral hemisphere under general anaes-
thesia (n = 6, 5 castrated males and 1 female, 10–12
months old). Control animals (n = 2, female, 10–12
months old) underwent an identical procedure with ster-
ile normal saline containing 1.25 mg/ml ampicillin. All
animals were observed daily for clinical signs of disease
and weighed monthly.
Genotyping
Genotyping was performed either from blood samples
taken from live deer into vacutainers containing EDTA
(BD Bioscience, Erembodegem, Belgium) or from frozen
brain material collected post-mortem. DNA was extracted
from blood using the CST Genomic DNA Purification Kit
(Charge Switch™ Technology, DNA Research Innovations,
Ltd., Sittingbourne, UK) and from frozen brain tissue
using the DNeasy Blood & Tissue kit (Qiagen, Hilden,
Germany) according to manufacturers' instructions. PCR
amplification of genomic DNA was carried out using PCR
primers C.e. 19fwd 5' ATT TTG CAG ATA AGT CAT C 3'
and C.e. 778rev 5' AGA AGA TAA TGA AAA CAG GAA G
3' [21]. The PCR reaction was carried out using a hot start
of 95°C, 15 min then 10 cycles of 94°C for 30 sec, 55°C
for 30 sec, 72°C for 45 sec then 30 cycles of 95°C for 30
sec, 59°C for 30 sec, 72°C for 59 sec. Amplified samples
were then sequenced by the dideoxy chain termination
method using ET terminator chemistry using a MegaBACE
500 instrument and Cimarron 3.12 basecaller (GE
Healthcare, Amersham plc., Buckinghamshire, UK).
Post-mortem examination
The 6 BSE challenged deer (5 males and 1 female), and 2
clinically normal negative control deer (both female)
were subjected to full post-mortem examination and an
extensive range of tissue samples taken from: 1) the nerv-
ous system (brain and pituitary, cervical, thoracic and
lumbar spinal cord with associated dorsal root ganglia,
the trigeminal, nodose, stellate and cranial mesenteric
ganglia, the vagus nerve, the sympathetic chain, the sec-
ond muscular branch of the sciatic nerve and the eye), 2)
the lymphoreticular system (third eyelid, submandibular,
retropharyngeal, prescapular, mediastinal, popliteal and
proximal and distal jejunal lymph nodes, the palatine
tonsil and spleen), gastro-intestinal tract (oesophagus,
omasum, abomasum, duodenum, jejunum, distal ileum
and colon all with their associated Payer's patches and the
caecum), 3) body fluids (cerebrospinal fluid, blood
serum, blood buffy coat and urine), and 4) other tissues
(skin of the ventral lip, inter-ventricular septum of the
heart, left caudal lung lobe, liver, kidney, semitendinosus
muscle and uterus and mammary gland if present). All
samples were fixed in 10% neutral buffered formalin and/
or frozen and stored at -80°C. Fixed samples were post-
fixed in fresh 10% neutral buffered formalin then rou-
tinely processed for embedding in paraffin wax. Four μm
thick sections were cut and mounted on glass slides
(Superfrost Plus; Menzel-Gläser, Braunschweig, Ger-
many) and either stained with haematoxylin and eosin or
subjected to IHC.
Immunohistochemical localisation of PrPd
This was performed as previously described [33]. Briefly,
antigen retrieval included immersion in 98% formic acid
for 5 minutes followed by autoclaving for 30 minutes at
121°C in 0.2% citrate buffer. Endogenous peroxidase
activity was quenched with 0.9% (v/v) hydrogen peroxide
in distilled water for 20 minutes and to block reactivity of
non-specific tissue antigens sections were incubated in
20% normal horse serum for 1 hour. Following this, incu-
bation with the primary antibody was carried out over-
night at 27°C. The subsequent steps of the IHC protocol
were performed by a commercial immunoperoxidase
technique (Vector-elite ABC kit; Vector Laboratories,
Peterborough, UK) at the end of which sections were
immersed in 0.5% copper sulphate to enhance any immu-
noperoxidase colour reaction and finally counterstained
with Mayer's haematoxylin prior to routine dehydration
and mounting. Primary antibodies were either F99, clone
97.6.1 (VMRD Inc., Pullman, USA), which binds to
amino acid sequence 220–225 of human PrP or BAR224
(CEA, Saclay, France) which recognizes amino acid
sequence 141–147. Both of these antibodies have wide
inter-species reactivity.
Western immunoblot analysis of brain samples
Samples of frozen cerebellum were allowed to warm to
room temperature and homogenised at 10% (w/v) in lysis
buffer (tris-buffered saline [TBS] pH 7.4, 0.5% Na-deoxy-
cholate, 0.5% NP-40) with a Fast Prep instrument (Q-bio-
gene, Cambridge, UK) using 1 cycle of 6.0 ms/40 sec.
Lysates were held at 4°C for 2 h then centrifuged 100 × g
for 1 minute and aspirated to new tubes avoiding any
remaining tissue debris. 100 μl of lysate was treated with
proteinase K solution (50 μg/ml) for 1 hour at 37°C with
shaking. Digestion was terminated by adding Pefabloc SC
(Roche Diagnostics, Burgess Hill, West Sussex, UK) to a
concentration of 1 mM. Samples were then centrifuged at
20,000 × g for 1 hour at 10°C. Supernatants were dis-
carded and pellets resuspended in 45 μl 2 × SB (Invitro-
gen, Paisley, UK) containing 5 μl of 10 × sample reducing
agent (Invitrogen, Paisley, UK). Samples were heated atBMC Veterinary Research 2008, 4:17 http://www.biomedcentral.com/1746-6148/4/17
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100°C for 5 minutes then briefly centrifuged for 5 sec-
onds at 20,000 × g. SDS-PAGE was carried out on 5–20 μl
of sample on 12% Bis-Tris NuPAGE gels (Invitrogen, Pais-
ley, UK) at 150 V for 1 hour. One mg brain equivalent was
loaded for each sample except for BSE, experimental ovine
BSE and deer 1 all of which had 1.5 mg loaded to enable
visible staining on the resultant Western blots. Proteins
were electrotransferred onto Hybond P PVDF membrane
(GE Healthcare, Chalfont St Giles, Buckinghamshire, UK)
at 30 V for 1 hour. Non-specific antigen binding on the
membrane was blocked by soaking in 5% non-fat milk/
TBS with 0.1% Tween20  (Sigma Chemical Company,
Poole, Dorset, UK) and probed with either antibody L42
(R-biopharm, Darmstadt, Germany, diluted 1:2000),
which binds to amino acid sequence of 145–163 of ovine
PrP, or antibody P4 (R-biopharm, Darmstadt, Germany,
diluted 1:2000), which binds to amino acids WGQGGSH
(sequence 93–99 of ovine PrP) [34]. A Western immuno-
blot was also prepared from identical samples with the
omission of the proteinase K digestion step and labelled
with antibody P4. Signal was detected using Super Signal
West Fempto Maximum Sensitivity Substrate (Pierce,
Rockford, IL, USA) and a Kodak IS440 image station
(Labtech International Ltd., Lewes, UK). The relative
intensities of the di-, mono- and aglycosyl bands of PrPres
were determined by scanning the Western blot image
using Kodak 1D Image Analysis Software.
Statistical analysis of Western immunoblot
Each of the three relevant bands (di-, mono-, and unglyc-
osylated) positive for protease resistant PrP by labelling
with antibody L42 on Western immunoblots were ana-
lysed separately for distance migrated using a linear mixed
model with the type of sample included as a fixed effect in
the model and blot included as a random effect in the
model. The parameters in the model were estimated using
the REML directive in Genstat 10th edition. Using this
model accounts for the differences in mean levels between
blots for each type of band separately (as opposed to sub-
tracting off a constant amount from all the readings on
one blot to allow for differences between them). The three
bands in a single column are not independent of each
other and so the results from the three separate analyses
are likely to be correlated. Data were available from five
replicate Western immunoblots each containing samples
representing scrapie, experimental ovine BSE, bovine BSE
and the six BSE challenged clinically affected deer (only
five samples for i/c challenged deer were present on three
of the blots, deer 6 was absent) and the two negative con-
trol animals (which did not label for protease resistant
PrP). Samples were considered to be significant at p ≤
0.05.
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